Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies. CDK4/6 inhibitors show promise ...

Outpatient administration of CAR T-cell therapies can reduce costs and improve patient satisfaction, with evolving ...

In this context, a study appearing in Frontiers of Medicine explores the potential of dronedarone, an FDA-approved drug, in inhibiting ESCC proliferation through the CDK4/CDK6-RB1 axis ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment ...

Jhaveri and colleagues also evaluated imlunestrant in combination with the CDK4/6 inhibitor abemaciclib (Verzenio) versus ...

1) The epigenetic regulations in drug resistance. Our preliminary data revealed that epigenetic regulation is involved in the resistance to one chemotherapeutic, CDK4/6 inhibitor. We determine how an ...